10-Q: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Regulus Therapeutics reported a net loss of $8.5 million for the first quarter of 2024, while highlighting progress in its RGLS8429 clinical trial for ADPKD.

Summary

• Regulus Therapeutics reported a net loss of $8.5 million for the first quarter of 2024, compared to a net loss of $7.1 million for the same period in 2023.
• The company's research and development expenses increased to $6.0 million, up from $4.9 million in the first quarter of 2023, primarily due to increased external costs associated with clinical trials and preclinical studies.
• General and administrative expenses also rose to $2.8 million, compared to $2.4 million in the same period last year, mainly due to increased non-cash stock-based compensation.
• As of March 31, 2024, Regulus had cash, cash equivalents, and investments totaling $107.7 million.
• The company raised approximately $93.9 million in net proceeds from a private placement of common stock and non-voting convertible preferred stock in March 2024.
• The company's term loan matured on May 1, 2024, and all outstanding amounts were paid.
• The company is focused on the clinical development of RGLS8429 for autosomal dominant polycystic kidney disease (ADPKD), with positive topline results from the first two cohorts of the Phase 1b study.
• The company has completed enrollment of the third cohort of patients in the MAD study and initiated the fourth and final cohort.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While the company has made progress in its clinical trials and secured significant funding, it also reports increased losses and faces numerous risks typical of a clinical-stage biotech company. The sentiment is cautiously optimistic due to the clinical progress but tempered by the financial challenges.

Positives

• The company successfully raised $93.9 million through a private placement, strengthening its financial position.
• The company's RGLS8429 program for ADPKD continues to show positive results in clinical trials, with increased biological activity observed at higher doses.
• The company completed a chronic mouse toxicity study for RGLS8429 with no related toxicity observed.
• The company has completed enrollment of the third cohort of patients in the MAD study and initiated the fourth and final cohort.
• The company is in compliance with all loan agreement covenants.

Negatives

• The company experienced an increased net loss of $8.5 million in the first quarter of 2024 compared to $7.1 million in the same period of 2023.
• Research and development expenses increased to $6.0 million in the first quarter of 2024.
• General and administrative expenses also increased to $2.8 million in the first quarter of 2024.

Risks

• The company's approach to drug discovery is novel and may not lead to marketable products.
• Preclinical and clinical studies may not be successful, and results may not be indicative of future outcomes.
• The company may not obtain regulatory approval for its product candidates.
• The company has incurred significant losses and anticipates continuing to do so.
• The company relies on third parties for manufacturing and clinical trials, which could lead to delays or issues.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's stock price may be highly volatile.
• The company may need to raise additional capital, and there is no guarantee that it will be available on acceptable terms or at all.
• The company is subject to stringent and evolving laws, regulations, and rules related to data privacy and security.
• The company's business could be adversely affected by health pandemics or epidemics.

Future Outlook

The company believes its existing resources will fund planned operations for at least the next 12 months and intends to seek additional capital through equity and/or debt financings, collaborative or other funding arrangements.

Management Comments

• Management believes that micro RNA therapeutics have the potential to become a new and major class of drugs with broad therapeutic application.
• Management is using its micro RNA expertise to develop chemically modified, single-stranded oligonucleotides that they call anti-miRs to modulate micro RNAs and address underlying disease.
• Management believes micro RNAs may play a critical role in complex disease and that targeting them with anti-miRs may become a source of a new and major class of drugs.

Industry Context

The company is operating in the competitive biotechnology and pharmaceutical industries, focusing on microRNA therapeutics, a relatively new area of drug development. The company's focus on orphan kidney diseases aligns with a trend towards addressing unmet medical needs in rare diseases.

Comparison to Industry Standards

• Regulus's financial results are typical for a clinical-stage biotechnology company, with significant R&D spending and ongoing losses.
• The company's focus on microRNA therapeutics is a novel approach, and there are no direct comparables in terms of approved products.
• The company's cash runway of at least 12 months is a standard benchmark for biotech companies, but the need for future capital raises is a common risk.
• The company's R&D spending is in line with other companies at a similar stage of development, but the specific costs are dependent on the nature of the clinical trials and preclinical studies.
• The company's reliance on third-party manufacturers and CROs is a common practice in the industry, but it introduces risks related to supply chain and clinical trial execution.

Related Party Transactions

• Stelios Papadopoulos, Ph.D., Chairman of the Company's board of directors, was a 2024 Purchaser under the March 2024 SPA and purchased 250,000 shares of common stock for $0.4 million.
• Stelios Papadopoulos, Ph.D., Chairman of the Company's board of directors, was a 2023 Purchaser under the April 2023 SPA and purchased 222,198 shares of common stock for $0.2 million.

Stakeholder Impact

• Shareholders may experience dilution from future equity financings.
• Employees may be affected by potential restructuring activities.
• Patients with ADPKD may benefit from the development of RGLS8429.
• Collaborators and suppliers may be impacted by the company's financial performance and strategic decisions.
• Creditors may be affected by the company's ability to repay its debts.

Next Steps

• The company will continue enrollment and dosing in the Phase 1b MAD study of RGLS8429.
• The company will evaluate the efficacy of RGLS8429 treatment across different dose levels.
• The company will further explore the potential impact of targeting miR-17 on htTKV and TKCV in patients with ADPKD.
• The company will seek additional capital through equity and/or debt financings, collaborative or other funding arrangements.

Key Dates

Keywords

RGLS8429, ADPKD, microRNA, clinical trial, biotechnology, pharmaceutical, oligonucleotide, drug development, private placement, financial results